share_log

智云健康发布2023年业绩:全年大幅减亏约2.6亿,同比收窄77.4%,四季度扭亏为盈

Zhiyun Health announced its 2023 results: a sharp decrease of about 260 million dollars for the whole year, narrowing by 77.4% year-on-year, and turning losses into profits in the fourth quarter

Gelonghui Finance ·  Mar 21 22:20
GLONGHUI March 21 | Zhiyun Health (9955.HK) officially announced the 2023 performance report. The report shows that in 2023, Zhiyun Health's revenue continued to grow rapidly, with revenue reaching 3.69 billion yuan, an increase of 23.5% over the previous year. Among them, in-hospital solution revenue was 2.87 billion yuan, accounting for more than 70%, the largest revenue source, up 31.5% year on year; pharmacy solution revenue was 660 million yuan, up 6.9% year on year; and personal chronic disease management solutions and other revenue was 160 million yuan. Non-IFRS (non-IFRS) adjusted net loss narrowed to 75.1 million yuan, a year-on-year decrease of 77.4%. The fourth quarter became the company's first profitable quarter, turning losses into profits in a single quarter. By the end of 2023, the total amount of the company's cash and financial products was about 620 million, which was basically the same as in the medium term, and cash reserves were abundant. The company's three business segments go hand in hand, and revenue continues to grow. As of December 31, 2023, the number of hospitals equipped with MedicalExchange SaaS reached 2,719, an increase of 152 over the year ended December 31, 2022, or 5.9%. These include 815 level-III public hospitals and 1,134 level-II public hospitals. In addition, 40 of the 815 tertiary public hospitals are among the top 100 hospitals in China; there are more than 219,000 pharmacies with SaaS consultation systems, covering about 35% of pharmacies in China; the Internet hospital platform has more than 103,000 registered doctors, more than 31 million registered users, and more than 180 million online services, another record high. During the reporting period, under the guidance of the “hospital first” strategy and the “P2M” strategy, the company's business showed strong growth momentum. Looking ahead to 2024, the flywheel effect of the business model will also drive the company to further commercialize, and it is expected that a new round of rapid growth and overall profit will occur rapidly.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment